Relugolix (Orgovyx)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses relugolix, (Orgovyx), 120 mg, oral tablets. Indication: For the treatment of adult patients with advanced prostate cancer.